Physician profile
Barbara E Bolek
NPI 1629497748
$3,522.68
in general payments reported to CMS, 2019-2025
36 companies · $1,266 in 2025
The $1,266 reported for 2025 was more than what 87% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $492 · 2022: $385 · 2023: $585 · 2024: $795 · 2025: $1,266.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,645.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,645.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $633.56 | 2021-2025 | Zepbound, Jardiance, Mounjaro |
| Abbvie INC. | $585.21 | 2021-2025 | |
| Novo Nordisk INC | $320.22 | 2021-2025 | Ozempic, Rybelsus |
| Abbott Laboratories | $253.44 | 2022-2025 | Freestyle Libre 3, Proclaim, Freestyle Libre 2 |
| Astrazeneca Pharmaceuticals Lp | $229.83 | 2023-2025 | Airsupra, Breztri, Farxiga |
| Glaxosmithkline, LLC. | $183.10 | 2022-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Shockwave Medical, INC | $168.33 | 2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $151.08 | 2021-2025 | Jardiance |
| Axsome Therapeutics, INC. | $108.67 | 2024-2025 | Auvelity |
| Pfizer INC. | $79.51 | 2021-2025 | |
| Mayne Pharma Commercial LLC | $76.12 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $58.62 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $54.34 | 2021-2025 | Trintellix |
| Otsuka America Pharmaceutical, INC. | $52.70 | 2025 | Rexulti |
| Sumitomo Pharma America, INC. | $43.58 | 2025 | Gemtesa |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $40.48 | 2022-2025 | Nexplanon |
| Teva Pharmaceuticals USA, INC. | $39.20 | 2023 | Austedo Xr |
| Bausch Health US, LLC | $37.61 | 2024-2025 | Aplenzin |
| Exact Sciences Corporation | $37.13 | 2023 | Cologuard Collection Kit |
| Viiv Healthcare Company | $35.96 | 2024-2025 | Apretude |
| Amgen INC. | $32.08 | 2021-2024 | Otezla, Repatha |
| Stryker Corporation | $30.63 | 2022 | |
| Millicent US INC | $28.06 | 2025 | Femlyv |
| Sanofi-Aventis U.S. LLC | $27.28 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $27.16 | 2023 | |
| Merck Sharp & Dohme LLC | $26.74 | 2025 | Gardasil 9, Capvaxive |
| Convatec INC. | $23.44 | 2025 | |
| Medtronic, INC. | $20.83 | 2022 | |
| Ironshore Pharmaceuticals INC. | $19.38 | 2023 | Jornay Pm |
| Novartis Pharmaceuticals Corporation | $19.20 | 2021 | |
| Dexcom, INC. | $17.19 | 2025 | Dexcom G6 Transmitter |
| Janssen Pharmaceuticals, INC | $16.41 | 2021 | |
| Xeris Pharmaceuticals, INC. | $14.95 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.66 | 2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $12.65 | 2022 | |
| Genentech USA, INC. | $3.33 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barbara Bolek listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.